MPPE1 and cancer: Therapies aimed at increasing cDC1 abundance in tumors or facilitating their activation may therefore boost anti-tumor immunity and potentially increase the responsiveness of cancer patients to immunotherapy (Broz et al., 2014, Salmon et al., 2016, Spranger et al., 2017).